Brief: MediciNova Completes Patient Enrollment In MN-001 Trial For Tipelukast In MN-001-NATG-202 Study
04/11/2025 12:35
Nov 4 (Reuters) - MediciNova Inc MNOV.O: MEDICINOVA ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN MN-001-NATG-202 CLINICAL TRIAL OF MN-001 (TIPELUKAST) Source text: ID:nGNX5pjktR Further company coverage: MNOV.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicinova
See all newsBrief: 3D Investment Partners Cuts Stake In Medicinova To 9.88% From 11.22%, Filing Shows
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX
MediciNova falls as fatty liver drug misses significance on blood-fat reduction
US STOCKS ON THE MOVE-WhiteHawk, Nvidia, Snowflake